Provided by Tiger Trade Technology Pte. Ltd.

Eledon Pharmaceuticals, Inc.

3.45
-0.0700-1.99%
Post-market: 3.45-0.0050-0.14%19:55 EDT
Volume:743.92K
Turnover:2.58M
Market Cap:280.35M
PE:-3.50
High:3.58
Open:3.54
Low:3.41
Close:3.52
52wk High:4.60
52wk Low:1.35
Shares:81.26M
Float Shares:74.57M
Volume Ratio:0.83
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9867
EPS(LYR):-0.5566
ROE:-110.71%
ROA:-39.02%
PB:3.89
PE(LYR):-6.20

Loading ...

Clene Q2 Net Loss Widens on Higher Other Expenses

Reuters
·
Aug 14

Eledon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate

Benzinga Earnings
·
Aug 14

Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes

Reuters
·
Aug 14

Eledon Q2 FY26 Net Loss Widens to $31.6 Million

Reuters
·
Aug 14

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Aug 14

Eledon Pharmaceuticals Q2 Operating Expenses USD 22.869 Million

THOMSON REUTERS
·
Aug 14

Eledon Pharmaceuticals Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 10

NewcelX Prices USD 1.4 Million Private Placement at USD 4.03 Per Share

Reuters
·
Jul 31

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Simply Wall St.
·
Jul 25

Eledon Pharmaceuticals Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Jul 21

Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial

Reuters
·
Jun 25

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

THOMSON REUTERS
·
Jun 25

Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026

THOMSON REUTERS
·
Jun 25

Health Rounds: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial

Reuters
·
Jun 24

Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN)

TIPRANKS
·
Jun 23

Eledon Pharmaceuticals shareholders approve increase in authorized common shares to 450 million

Reuters
·
Jun 23

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Jun 23

Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus

MT Newswires Live
·
Jun 22

Eledon posts American Transplant Congress presentation on tegoprubart kidney transplant data update

Reuters
·
Jun 22